An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity

Proceedings of the Society for Experimental Biology and Medicine

Volumn 212, Issue 4, 1996, Pages 297-304

  Reasor, Mark J ^a   Kacew, Sam ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6,6' METHYLENEBIS(1,2 DIHYDRO 4 METHANESULFONYL 2,2 DIMETHYLQUINOLINE); AMIODARONE; ANTIOXIDANT; DEETHYLAMIODARONE; GLUTATHIONE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPID; SILIBININ; SUPEROXIDE;

CELL DAMAGE; CELL MEMBRANE; DRUG ACCUMULATION; DRUG METABOLISM; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; LIPIDOSIS; LUNG FIBROSIS; LUNG TOXICITY; NONHUMAN; OXIDATION; PATHOLOGY; SHORT SURVEY;

EID: 0029822284     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-212-44019     Document Type: Short Survey

References (89)

1. Mason JW. Amiodarone. N Engl J Med 316:455-466, 1987.
2. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 121:158-171, 1991.
3. Martin WJ II, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 1). Chest 93:1067-1075, 1988.
4. Martin WJ II, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest 93:1242-1246, 1988.
5. Pitcher WD. Southwestern internal medicine conference: Amiodarone pulmonary toxicity. Am J Med Sci 303:206-212, 1992.
6. Martin WJ II, Standing JS. Amiodarone pulmonary toxicity: Biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther 244:774-779, 1988.
7. Costa-Jussa FR, Corrin B, Jacobs JM. Amiodarone lung toxicity: A human and experimental study. J Pathol 143:73-79, 1984.
8. Colgan T, Simon GT, Kay JM, Pugsley SO, Eydt J. Amiodarone pulmonary toxicity. Ultrastruct Pathol 6:199-207, 1984.
9. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 97:839-845, 1982.
10. Dake MD, Madison JM, Montgomery CK, Shellito JE, Hinchcliffe WA, Winkler ML, Bainton DF. Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. Am J Med 78:506-512, 1985.
11. Akoun GM, Cadranel JL, Milleron BJ, D'Ortho MF, Mayaud CM. Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest 99:98-104, 1991.
12. Coudert B, Bailly F, Lonbard JN, Andre F, Camus P. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 102:1005-1012, 1992.
13. Darmanata JI, Van Zandwijk N, Duren DR, van Royen EA, Mooi WJ, Plomp TA, Jansen HM, Durrer D. Amiodarone pneumonitis: Three further cases with a review of published reports. Thorax 39:57-64, 1984.
14. Dean PJ, Groshart KD, Porterfield JG, Iansmith DH, Golden EB Jr. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 87:7-13, 1987.
15. Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone pulmonary toxicity: clinical, radiologic, and pathologic correlations. Arch Intern Med 147:50-55, 1987.
16. Sobol SM, Rakita L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug. Circulation 65:819-824, 1982.
17. Gefter WB, Epstein DM, Pietra GG, Miller WT. Lung disease caused by amiodarone, a new antiarrhythmic agent. Radiology 147:339-344, 1983.
18. Farmakis M, Litos G, Melissinos Ch, Vic P. Diffuse interstitial pulmonary disease during amiodarone treatment. Arzneim-Forsch/Drug Res 34:223-225, 1984.
19. Leech JA, Gallastegui J, Swiryn S. Pulmonary toxicity of amiodarone. Chest 85:444-445, 1984.
20. Adams PC, Gibson GJ, Morley AR, Wright AJ, Corns PA, Reid DS, Campbell RWF. Amiodarone pulmonary toxicity: clinical and subclinical features. QJM 59:229,449-471, 1986.
21. Pollak PT, Sami M. Acute necrotizing pneumonitis and hyperglycemia after amiodarone therapy. Am J Med 76:935-939, 1984.
22. Reasor MJ, Ogle CL, Walker ER, Kacew S. Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am Rev Respir Dis 137:510-518, 1988.
23. Kannan R, Sarma JSM, Guha M, Venkataraman K. Tissue accumulation and ultrastructural changes during amiodarone administration in rats. Fund Appl Toxicol 13:793-803, 1989.
24. Wilson BD, Carkson CE, Lippmann ML. Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite, and phospholipid. Am Rev Respir Dis 143:1110-1114, 1991.
25. Wang Q, Hollinger MA, Giri SN. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. J Pharmacol Exp Ther 262:127-132, 1992.
26. Vereckei A, Blazovics A, Gyorgy I, Feher E, Toth M, Szenasi G, Zsinka A, Foldiak G, Feher J. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 4:161-177, 1993.
27. Riva E, Marchi S, Pesenti A, Bizzi A, Cini M, Veneroni E, Tavbani E, Boeri R, Bertani T, Latini R. Amiodarone induced phospholipidosis: biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. Biochem Pharmacol 36:3209-3214, 1987.
28. Wilson BD, Jaworski AJ, Donner ME, Lippmann ML. Amiodarone-induced pulmonary toxicity in the rat. Lung 167:301-311, 1989.
29. Blake TL, Reasor MJ. Pulmonary responses to amiodarone in hamsters: Comparison of intratracheal and oral administrations. Toxicol Appl Pharmacol 131:325-331, 1995.
30. Cantor JO, Osman M, Cerreta JM, Suarez R, Mandl I, Turino GM. Amiodarone-induced pulmonary fibrosis in Hamsters. Exp Lung Res 6:1-10, 1984.
31. Daniels JM, Brien JF, Massey TE. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol Appl Pharmacol 100:350-359, 1989.
32. Dunn M, Glassroth J. Pulmonary complications of amiodarone toxicity. Prog Cardiovasc Dis 31:447-453, 1989.
33. Martin WJ II. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med 11:131-138, 1990.
34. Reasor MJ, Kacew S. Amiodarone pulmonary toxicity: Morphologic and biochemical features. Proc Soc Exp Biol Med 196:1-7, 1990.
35. Fraire AE, Guntupalli KK, Greenberg SD, Cartwright J Jr., Chasen MH. Amiodarone pulmonary toxicity: A multidisciplinary review of current status. S Med J 86:67-77, 1993.
36. Mason JW: Prediction of amiodarone-induced pulmonary toxicity. Am J Med 86:2, 1989.
37. Martin WJ II, Howard DM. Amiodarone-induced lung toxicity. In vitro evidence for the direct toxicity of the drug. Am J Pathol 120:344-350, 1985.
38. Ogle CL, Reasor MJ. Response of alveolar macrophages to amiodarone and desethylamiodarone, in vitro. Toxicology 62:227-238, 1990.
39. Wilson BD, Lippmann ML. Pulmonary accumulation of amiodarone and N-desethylamiodarone. Relationship to the development of pulmonary toxicity. Am Rev Respir Dis 141:1553-1558, 1990.
40. Heath MF, Costa-Jussa FR, Jacobs JM, Jacobson W. The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br J Exp Pathol 66:91-397, 1985.
41. Hostetler KY, Reasor MJ, Walker ER, Yazaki PJ, Frazee BW. Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim Biophys Acta 875:400-405, 1986.
42. Martin WJ II, Kachel DL, Vilen T, Natarajan V. Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther 251:272-278, 1989.
43. 14C]amiodarone uptake by perfused lung. Am J Respir Cell Mol Biol 4:369-378, 1991.
44. Reasor MJ, McCloud CM, Beard TL, Ebert DC, Kacew S, Gardner MF, Aldern KA, Hostetler KY. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology 106:139-147, 1996.
45. Camus P, Jeannin L. Speculation on the mechanism for amiodarone-induced pneumonitis. Radiology 150:279-280, 1984.
46. Liu FL, Cohen RD, Downar E, Butany JW, Edelson JD, Rebuck AS. Amiodarone pulmonary toxicity: Functional and ultrastructural evaluation. Thorax 41:100-105, 1986.
47. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: Pathologic findings in clinically toxic patients. Hum Pathol 18:349-354, 1987.
48. Nicolet-Chatelain G, Prevost M-C, Escamilla R, Migueres J. Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. Chest 99:363-369, 1991.
49. Canada AT, Lesko LJ, Haffajee CI, Johnson B, Asdourian GK. Amiodarone for tachyarrhythmias: Pharmacology, kinetics, and efficacy. Drug Intell Clin Pharmacol 17:100-104, 1983.
50. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Phys Pharmacol 65:360-364, 1987.
51. Reasor MJ, Ogle CL, Kacew S. Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics. Toxicol Appl Pharmacol 97:124-133, 1989.
52. Bandyopadhyay S, Somani P. A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. J Cardiovasc Pharmacol 10:379-388, 1987.
53. Brien JF, Jimmo S, Brennan FJ, Armstrong PW, Abdollah H. Disposition of amiodarone and its proximate metabolile, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. Drug Metab Dispos 18:846-851, 1990.
54. Rotmensch HH, Liron M, Tupilski M, Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J 100:412-413, 1980.
55. Akoun GM, Gauthier-Rahman S, Milleron BJ, Perrot JY, Mayaud CM. Amiodarone-induced hypersensitivity pneumonitis: evidence of an immunological cell-mediated mechanism. Chest 85:133-135, 1984.
56. Fan K, Bell R, Eudy S, Fullenwider J. Amiodarone-associated pulmonary fibrosis: Evidence of an immunologically mediated mechanism. Chest 92:625-630, 1987.
57. Pichler WJ, Schindler L, Staubli M, Stadler BM, de Weck AL. Anti-amiodarone antibodies: Detection and relationship to the development of side effects. Am J Med 85:197-202, 1988.
58. Manicardi V, Bernini G, Bossini P, Bertorelli G, Pesci A, Bellodi G. Low-dose amiodarone-induced pneumonitis: evidence of an immunologic pathogenetic mechanism. Am J Med 86:134-135, 1989.
59. Joelson J, Kluger J, Cole S, Conway M. Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy. Chest 85:284-286, 1984.
60. Dan M, Greif J. Amiodarone and pneumonitis. Ann Intern Med 99:732, 1983.
61. Israel-Biet D, Venet A, Caubarrere I, Bonan G, Danel C, Chretien J, Hance AJ. Bronchoalveolar lavage in amiodarone pneumonitis: Cellular abnormalities and their relevance to pathogenesis. Chest 91:214-221, 1987.
62. Ohar JA, Jackson F, Dettenmeier PA, Bedrossian CW, Tricomi SM, Evans RG. Bronchoalveolar lavage cell counts and differential are not reliable indicators of amiodarone-induced pneumonitis. Chest 102:999-1004, 1992.
63. Karpel JP, Mitsudo S, Norin AJ. Natural killer cell activity in a rat model of amiodarone induced interstitial lung disease. Chest 99:230-234, 1991.
64. Wilson BD, Lippmann ML. Amiodarone pulmonary toxicity in the rat is associated with increased lavage immunoglobulin and alveolar macrophages primed for increased interleukin-1 secretion. Am J Respir Cell Mol Biol 9:295-299, 1993.
65. Reasor MJ, McCloud CM, DiMatteo M, Schafer R, Ima A, Lemaire I. Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Proc Soc Exp Biol Med 211:346-352, 1996.
66. Kennedy TP, Gordon GB, Paky A, McShane A, Adkinson NF, Peters SP, Friday K, Jackman W, Sciuto AM, Gurtner GH. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol 12:23-36, 1988.
67. Kachel DL, Moyer TP, Martin WJ II. Amiodarone-induced injury of human pulmonary artery endothelial cells: Protection by alpha-tocopherol. J Pharmacol Exp Ther 254:1107-1112, 1990.
68. Honegger UE, Scuntaro I, Wiesmann UN. Vitamin E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochem Pharmacol 49:1741-1745, 1995.
69. Lucy JA. Functional and structural aspects of biological membranes: A suggested structural role of vitamin E in the control of membrane permeability and stability. Ann NY Acad Sci 203:4-11, 1972.
70. Diplock AT. The modulating influence of vitamin E in biological membrane and unsaturated phospholipid metabolism. Acta Vitaminol Enzymol 4:303-309, 1982.
71. Leeder RG, Brien JF, Massey TE. Investigation of oxidative stress in amiodarone-induced pulmonary toxicity in the hamster. Can J Physiol Pharmacol 72:613-621, 1994.
72. Zitnik RJ, Cooper JAD Jr., Rankin JA, Sussman J. Effects of in vitro amiodarone exposure on alveolar macrophage inflammatory mediator production. Am J Med Sci 304:352-356, 1992.
73. Sautereau A-M, Tournaire C, Sauares M, Tocanne J-F, Paillous N. Interactions of amiodarone with model membranes and amiodarone-photo-induced peroxidation of lipids. Biochem Pharmacol 43:2559-2563, 1992.
74. Chatelain P, Brotelle R. Phospholipid composition of rat lung after amiodarone treatment. Res Commun Chem Pathol Pharmacol 50:407-418, 1985.
75. Chatelain P, Ferreira J, Laruel R, Ruysschaer JM. Amiodarone induced modifications of the phospholipid physical state. A fluorescence polarization study. Biochem Pharmacol 35:3007-3013, 1986.
76. Chatelain P, Laruel R, Vic P, Brotelle R. Differential effects of amiodarone and propranolol on lipid dynamics and enzymatic activities in cardiac sarcolemmal membranes. Biochem Pharmacol 38:1231-1239, 1989.
77. Herbette LG, Trumbore M, Chester DW, Katz AM. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: Propanolol, nimodipine, and amiodarone. J Mol Cell Cardiol 20:373-378, 1988.
78. Josh UM, Kodavanti PRS, Coudert B, Dwyer TM, Mehendale HM. Types of interactions of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther 246:150-157, 1988.
79. Joshi UM, Kodavanti PRS, Lockard VG, Mehendale HM. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: Relevance to phospholipidosis. Biochim Biophys Acta 1004:309-320, 1989.
80. Jendrasiak GL, McIntosh TJ, Ribeiro A, Porter RS. Amiodarone-liposome interaction: A multinuclear NMR and x-ray diffraction study. Biochim Biophys Acta 1024:19-31, 1990.
81. Honegger UE, Zuehlke RD, Scuntaro I, Schaefer MHA, Toplak H, Wiesmann UN. Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells. Biochem Pharmacol 45:349-356, 1993.
82. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 42:327-354, 1990.
83. 2+ associated with cellular injury to human pulmonary artery endothelial cells. Toxicol Appl Pharmacol 103:156-164, 1990.
84. Hagelueken A, Nuernberg B, Harhammer R, Gruenbaum L, Schunack W, Siefert R. The class III antiarrhythmic drug amiodarone directly activates pertussis toxin-sensitive G proteins. Mol Pharmacol 47:234-240, 1995.
85. Wilson BD, Clarkson CE, Lippmann ML. Amiodarone causes decreased cell-mediated immune responses and inhibits the phospholipase C signaling pathway. Lung 170:137-148, 1993.
86. Duane PG, Rice KL, Carboneau DE, Niewoehner DE. Amiodarone-induced endothelial injury is associated with phospholipid C-mediated hydrolysis of membrane phospholipids. J Lab Clin Med 120:955-963, 1992.
87. Kudenchuk PJ, Pierson DJ, Greene HL, Graham EL, Sears GK, Trobaugh GB. Prospective evaluation of amiodarone pulmonary toxicity. Chest 86:541-548, 1984.
88. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, Heger JJ. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82:51-59, 1990.
89. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin H-T, Wyndham CRC. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 12:781-788, 1988.